PMC10050453_01
Age and gender distribution in Pneumocystis jirovecii pneumonia signal cases of ICIs. Abbreviation: PJP, Pneumocystis jirovecii pneumonia. ROR, reporting odds ratio. IC, information component. 95%CI, 95% confidence interval. N, number. AEs, adverse events. ICIs, immune checkpoint inhibitors.
fphar-14-1129730-g003.jpg
PMC10050453_01_fphar-14-1129730-g003.jpg
F3
Males is the predominance in PJP case reports of across all ICIs (IC025 0.26, p < 0.001), nivolumab (IC025 0.20, p < 0.001), pembrolizumab (IC025 0.23, p < 0.001), ipilimumab (IC025-0.13, p = 0.015), nivolumab plus ipilimumab (IC025-0.18, p = 0.029). (Figure 3).
PMC10050453_02
The comparison of Pneumocystis jirovecii pneumonia signal between ICIs and targeted therapy/chemotherapy in FAERS database. The list of control group (targeted therapy and chemotherapy) was extracted from NCCN guidelines for FDA approved indication of ICIs. Abbreviation: PJP, Pneumocystis jirovecii pneumonia. ROR, reporting odds ratio. IC, information component. 95%CI, 95% confidence interval. N, number. AEs, adverse events. ICIs, immune checkpoint inhibitors. NCCN, National Comprehensive Cancer Network.
fphar-14-1129730-g002.jpg
PMC10050453_02_fphar-14-1129730-g002.jpg
F2
Table 4. The quality appraisal of the cases identified from the literature are summarized in Supplementary Figure S2.